"Many women are interested in managing their menstrual cycle individually, and are looking for a way to minimize the number of bleedings. With our new contraceptive regimen we will address this need in addition to providing reliable contraception. Our clinical studies have shown that this new regimen enables women to individually adapt their cycle length and to have a maximum period-free interval of up to 120 days," said Dr. Flemming Oernskov, Head of Women’s Healthcare & General Medicine at Bayer Healthcare.
The new regimen involves a daily intake for a minimum period of 24 days and up to a maximum period of 120 days. During this interval (day 25 to 120) women can schedule the 4-day tablet-free interval individually. A new cycle begins after each tablet-free interval. It has been shown that fewer bleeding episodes per year can help to reduce menstrual symptoms.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of more than EUR 15.9 billion (2009), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 53.400 employees and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.